Matters arising: On the cost-effectiveness for the Italian National Health Service of nab-paclitaxel plus gemcitabine vs gemcitabine alone in metastatic pancreatic cancer.
Carlo Lazzaro
Author Information
- Carlo Lazzaro: Studio di Economia Sanitaria, Via Stefanardo da Vimercate, 19, Milan, 20128, Italy. carlo.lazzaro@tiscalinet.it. ORCID
No abstract text available.
- Pharmacoeconomics. 2008;26(9):733-44
[PMID: 18767894]
- Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):435-446
[PMID: 29641931]
- J Egypt Public Health Assoc. 2024 Jun 3;99(1):12
[PMID: 38825614]
- Med Decis Making. 1993 Oct-Dec;13(4):322-38
[PMID: 8246705]
